Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

This protocol provides a streamlined workflow to generate and test human chimeric antigen receptor regulatory T cells (CAR Tregs).

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has reshaped the face of cancer treatment, leading to record remission rates in previously incurable hematological cancers. These successes have spurred interest in adapting the CAR platform to a small yet pivotal subset of CD4+ T cells primarily responsible for regulating and inhibiting the immune response, regulatory T cells (Tregs). The ability to redirect Tregs' immunosuppressive activity to any extracellular target has enormous implications for creating cell therapies for autoimmune disease, organ transplant rejection, and graft-versus-host disease. Here, we describe in detail methodologies for bona fide Treg isolation from human peripheral blood, genetic modification of human Tregs utilizing either lentivirus or CRISPR/Cas9-aided knock-in using adeno-associated virus-mediated homologous directed repair (HDR) template delivery, and ex vivo expansion of stable human CAR Tregs. Lastly, we describe the assessment of human CAR Treg phenotypic stability and in vitro suppressive function, which provides insights into how the human CAR Tregs will behave in preclinical and clinical applications.

Introduction

Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of hematological malignancies, achieving remarkably high remission rates in previously untreatable cancers1,2. Encouraging early results using CAR T cells to treat glioblastoma3,4,5 highlight CAR technology's versatility and future potential to target a wide range of malignancies. As the field explores further applications of CARs, regulatory T cells (Tregs) have emerged as a promising cell type. Tregs play a crucial role in maintai....

Protocol

1. Human Treg isolation

  1. Leukopak processing
    1. Transfer the contents of the leukopak into a 50 mL conical tube. Add an equal volume of Dulbecco's phosphate-buffered saline (DPBS) +2% fetal bovine serum (FBS) by mixing gently with a pipette.
    2. Spin at 300 × g for 10 min at room temperature (RT). Carefully aspirate the supernatant. Reconstitute the cell pellet in 2 mL of DPBS + 2% FBS. Add 8 mL of ammonium chloride solution by pipette to the cell suspension a.......

Representative Results

The protocol described here provides a streamlined and standardized pipeline to assess new chimeric antigen receptor (CAR) constructs in human regulatory T cells (Tregs), with the aim of creating living therapeutics for autoimmune disease, graft-versus-host disease, organ transplant rejection, and allergy. Figure 1 depicts how we obtain highly pure human Tregs from peripheral blood using FACS (Figure 1A), as evaluated by their high levels of the Treg lineage tra.......

Discussion

This protocol provides a streamlined and comprehensive methodology for generating and evaluating human chimeric antigen receptor regulatory T cells (CAR Tregs). The success of CAR technology in treating hematological cancers has inspired its application to the immunosuppressive subset of T cells, Tregs. Unlike conventional T cells, Tregs inhibit immune responses, offering potential treatments for conditions resulting from unwanted immunity, such as autoimmune disease, organ transplant rejection, graft-versus-host disease.......

Acknowledgements

LMRF is funded by Human Islet Research Network (HIRN) Emerging Leader in Type 1 Diabetes grant U24DK104162-07, American Cancer Society (ACS) Institutional Research Grant IRG-19-137-20, South Carolina Clinical and Translational Research (SCTR) Pilot Project Discovery Grant 1TL1TR001451-01, Diabetes Research Connection (DRC) Grant IPF 22-1224, and Swim Across America Grant 23-1579. RWC is supported by the Cellular, Biochemical and Molecular Sciences training grant T32GM132055 and Hollings Cancer Center Lowvelo Graduate Fellowship. This study was supported in part by the Flow Cytometry and Cell Sorting Shared Resource, Hollings Cancer Center, Medical University of South ....

Materials

NameCompanyCatalog NumberComments
Adeno-associated virus (AAV)Charles River Laboratories
CAR target-expressing K562 cellse.g., CD19-K562
Cesium-137 irradiator
Anti-human CD8 PerCP (clone SK1)Biolegend344708
Anti-human CD4 PE/Cy7 (clone SK3)Biolegend344612
DynaMag-15 magnetThermoFisher12301D
Ghost BV510 viability dye TONBO13-0870-T100
K562 cellsAmerican Type Culture CollectionCCL-243
0.5 M EDTA, pH 8.0Gibco 15575020
1 M HEPESGibco15630080
Ammonium chloride solutionSTEMCELL Technologies7850
Anti-human CD127 PE (clone hIL-7R-M21)BD Biosciences557938
Anti-human CD25 APC (clone BC96)Biolegend 302610
Anti-human CD4 FITC (clone SK3)Biolegend 344604
Anti-human CD71 PE (clone SK1)Biolegend334106
Anti-human CD8 PerCP (clone SK1)Biolegend 344707
Anti-human CTLA-4 PerCP-e710ThermoFisher46-1529-42
Anti-human EGFR APC (clone AY13)Biolegend352905
Anti-human FOXP3 eFluor 450ThermoFisher48-4776-42
Anti-human HELIOS PEBiolegend137216
Ca2+ and Mg2+ free Dulbecco’s Phosphate Buffered Saline (DPBS) Gibco14190144
Cell counter (TC20 Automated Cell Counter)Bio-Rad1450102
Cell Counting SlidesBio-Rad1450016
CellTrace Violet Cell Proliferation KitThermoFisherC34571
DNA LoBind TubesEppendorf22431021
Easy 50 EasySep magnet STEMCELL Technologies18002
EasySep Human CD4+ T cell Enrichment KitSTEMCELL Technologies19052
EasySep Human CD8+ T cell Enrichment KitSTEMCELL Technologies19053
EasySep magnet STEMCELL Technologies18000
eBioscience Foxp3 transcription factor staining buffer setThermoFisher00-5523-00
Falcon Round-Bottom Polystyrene Test Tubes with Cell Strainer Snap Cap, 5 mLFisher Scientific08-771-2340μm
Fetal Bovine Serum (FBS)Gibco26140079
Flow cytometerBeckman CoulterCytoFLEX LX U3-V5-B3-Y5-R3-I2
Fluorescence-activated cell sorterBD BiosciencesFACS Aria III Cell Sorter
GlutaMAXGibco35050061
Human CD3/28 T Cell Expansion and Activation DynabeadsGibco11131D
Invitrogen Neon Transfection SystemThermoFisher10431915
Invitrogen Neon Transfection System 100 μL KitThermoFisher10114334
LentivirusVectorBuilder
MEM Non-Essential Amino Acids Solution Gibco11140050
Myc Tag antibody A647 (clone 9B11)Cell Signaling Technologies2233S
Opti-MEM I Reduced Serum MediumThermoFisher31985062
Penicilin-Streptomycin solutionGibco15140122
Recombinant human interleukin-2 (rhIL-2)Peprotech200-02
RPMI 1640 medium, no glutamine Gibco11875093
Sodium pyruvateGibco11360070
Spectral Flow CytometerCytekNorthern Lights
TRAC gRNASynthegoSequence (CAGGGTTCTGGATATCTGT)
TrueCut Cas9 Protein v2ThermoFisherA36496
Trypan Blue solution Sigma T8154-100ML
1/10 LeukopakSTEMCELL Technologies200-00921-2 billion PBMC

References

  1. Zhang, X., Zhu, L., Zhang, H., Chen, S., Xiao, Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 13, 927153 (2022).
  2. Cappell, K. M., Kochenderfer, J. N.

Explore More Articles

Immunology and Infection

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved